Phase 1 Relapsed or Refractory Hematologic Malignancies Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals42 enrolled11 locationsNCT03838926
Recruiting
Phase 1
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07173595
Recruiting
Phase 1
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
Sinocelltech Ltd.74 enrolled1 locationNCT06252298